Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Risk factors profile of young and older patients with myocardial infarction
Myocardial infarction (MI) among young adults (< 45 years) represents a considerable
proportion of the total heart attack incidents. The underlying pathophysiologic …
proportion of the total heart attack incidents. The underlying pathophysiologic …
[HTML][HTML] PCSK9 inhibition: from current advances to evolving future
C Liu, J Chen, H Chen, T Zhang, D He, Q Luo, J Chi… - Cells, 2022 - mdpi.com
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a secretory serine protease
synthesized primarily by the liver. It mainly promotes the degradation of low-density …
synthesized primarily by the liver. It mainly promotes the degradation of low-density …
Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes
BA Ference, JG Robinson, RD Brook… - … England Journal of …, 2016 - Mass Medical Soc
Background Pharmacologic inhibitors of proprotein convertase subtilisin–kexin type 9
(PCSK9) are being evaluated in clinical trials for the treatment of cardiovascular disease …
(PCSK9) are being evaluated in clinical trials for the treatment of cardiovascular disease …
[HTML][HTML] Efficacy and safety of alirocumab in reducing lipids and cardiovascular events
JG Robinson, M Farnier, M Krempf… - … England Journal of …, 2015 - Mass Medical Soc
Background Alirocumab, a monoclonal antibody that inhibits proprotein convertase subtilisin–
kexin type 9 (PCSK9), has been shown to reduce low-density lipoprotein (LDL) cholesterol …
kexin type 9 (PCSK9), has been shown to reduce low-density lipoprotein (LDL) cholesterol …
Efficacy and safety of evolocumab in reducing lipids and cardiovascular events
MS Sabatine, RP Giugliano, SD Wiviott… - … England Journal of …, 2015 - Mass Medical Soc
Background Evolocumab, a monoclonal antibody that inhibits proprotein convertase
subtilisin–kexin type 9 (PCSK9), significantly reduced low-density lipoprotein (LDL) …
subtilisin–kexin type 9 (PCSK9), significantly reduced low-density lipoprotein (LDL) …
PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled …
Background Heterozygous familial hypercholesterolaemia is characterised by low cellular
uptake of LDL cholesterol, increased plasma LDL cholesterol concentrations, and premature …
uptake of LDL cholesterol, increased plasma LDL cholesterol concentrations, and premature …
PCSK9 inhibitors: a new era of lipid lowering therapy
Hyperlipidemia is a well-established risk factor for develo** cardiovascular disease
(CVD). The recent American College of Cardiology and American Heart Association …
(CVD). The recent American College of Cardiology and American Heart Association …
Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial
Background Homozygous familial hypercholesterolaemia is a rare, serious disorder caused
by very low or absent plasma clearance of LDL, substantially raised LDL cholesterol, and …
by very low or absent plasma clearance of LDL, substantially raised LDL cholesterol, and …
A 52-week placebo-controlled trial of evolocumab in hyperlipidemia
Background Evolocumab, a monoclonal antibody that inhibits proprotein convertase
subtilisin/kexin type 9 (PCSK9), significantly reduced low-density lipoprotein (LDL) …
subtilisin/kexin type 9 (PCSK9), significantly reduced low-density lipoprotein (LDL) …
Effect of evolocumab or ezetimibe added to moderate-or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 …
JG Robinson, BS Nedergaard, WJ Rogers, J Fialkow… - Jama, 2014 - jamanetwork.com
Importance In phase 2 studies, evolocumab, a fully human monoclonal antibody to PCSK9,
reduced LDL-C levels in patients receiving statin therapy. Objective To evaluate the efficacy …
reduced LDL-C levels in patients receiving statin therapy. Objective To evaluate the efficacy …